838
Views
11
CrossRef citations to date
0
Altmetric
Addendum

Unfolded protein response, treatment and CMT1B

, &
Article: e24049 | Received 11 Feb 2013, Accepted 19 Feb 2013, Published online: 20 Feb 2013

References

  • Patzkó A, Bai Y, Saporta MA, Katona I, Wu X, Vizzuso D, et al. Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice. Brain 2012; 135:3551 - 66; http://dx.doi.org/10.1093/brain/aws299; PMID: 23250879
  • Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth’s disease. Clin Genet 1974; 6:98 - 118; http://dx.doi.org/10.1111/j.1399-0004.1974.tb00638.x; PMID: 4430158
  • Nelis E, Van Broeckhoven C, De Jonghe P, Löfgren A, Vandenberghe A, Latour P, et al. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet 1996; 4:25 - 33; PMID: 8800924
  • Saporta ASD, Sottile SL, Miller LJ, Feely SM, Siskind CE, Shy ME. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011; 69:22 - 33; http://dx.doi.org/10.1002/ana.22166; PMID: 21280073
  • Trapp BD, Pfeiffer SE, Anitei A, Kidd GJ. Cell Biology and myelin assembly. In: Lazzarini RA ed, Myelin Biology and Disorders. San Diego/London: Elsevier Academic Press; 2003:29-56.
  • Shy ME, Jáni A, Krajewski KM, Grandis M, Lewis RA, Li J, et al. Phenotypic clustering in MPZ mutations. Brain 2004; 127:371 - 84; http://dx.doi.org/10.1093/brain/awh048; PMID: 14711881
  • Grandis M, Vigo T, Passalacqua M, Jain M, Scazzola S, La Padula V, et al. Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations. Hum Mol Genet 2008; 17:1877 - 89; http://dx.doi.org/10.1093/hmg/ddn083; PMID: 18337304
  • Khajavi M, Inoue K, Wiszniewski W, Ohyama T, Snipes GJ, Lupski JR. Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants. Am J Hum Genet 2005; 77:841 - 50; http://dx.doi.org/10.1086/497541; PMID: 16252242
  • Pennuto M, Tinelli E, Malaguti M, Del Carro U, D’Antonio M, Ron D, et al. Ablation of the UPR-mediator CHOP restores motor function and reduces demyelination in Charcot-Marie-Tooth 1B mice. Neuron 2008; 57:393 - 405; http://dx.doi.org/10.1016/j.neuron.2007.12.021; PMID: 18255032
  • Saporta MA, Shy BR, Patzko A, Bai Y, Pennuto M, Ferri C, et al. MpzR98C arrests Schwann cell development in a mouse model of early-onset Charcot-Marie-Tooth disease type 1B. Brain 2012; 135:2032 - 47; http://dx.doi.org/10.1093/brain/aws140; PMID: 22689911
  • Wrabetz L, D’Antonio M, Pennuto M, Dati G, Tinelli E, Fratta P, et al. Different intracellular pathomechanisms produce diverse Myelin Protein Zero neuropathies in transgenic mice. J Neurosci 2006; 26:2358 - 68; http://dx.doi.org/10.1523/JNEUROSCI.3819-05.2006; PMID: 16495463
  • Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glöckner-Pagel J, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004; 304:600 - 2; http://dx.doi.org/10.1126/science.1093941; PMID: 15105504
  • Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 2010; 103:1545 - 57; http://dx.doi.org/10.1017/S0007114509993667; PMID: 20100380
  • Khajavi M, Shiga K, Wiszniewski W, He F, Shaw CA, Yan J, et al. Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy. Am J Hum Genet 2007; 81:438 - 53; http://dx.doi.org/10.1086/519926; PMID: 17701891
  • Padhye S, Banerjee S, Chavan D, Pandye S, Swamy KV, Ali S, et al. Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm Res 2009; 26:2438 - 45; http://dx.doi.org/10.1007/s11095-009-9955-6; PMID: 19714451
  • Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 2007; 60:171 - 7; http://dx.doi.org/10.1007/s00280-006-0355-x; PMID: 17051370
  • Saher G, Rudolphi F, Corthals K, Ruhwedel T, Schmidt KF, Löwel S, et al. Therapy of Pelizaeus-Merzbacher disease in mice by feeding a cholesterol-enriched diet. Nat Med 2012; 18:1130 - 5; http://dx.doi.org/10.1038/nm.2833; PMID: 22706386
  • Inoue K, Osaka H, Sugiyama N, Kawanishi C, Onishi H, Nezu A, et al. A duplicated PLP gene causing Pelizaeus-Merzbacher disease detected by comparative multiplex PCR. Am J Hum Genet 1996; 59:32 - 9; PMID: 8659540
  • Saher G, Quintes S, Möbius W, Wehr MC, Krämer-Albers EM, Brügger B, et al. Cholesterol regulates the endoplasmic reticulum exit of the major membrane protein P0 required for peripheral myelin compaction. J Neurosci 2009; 29:6094 - 104; http://dx.doi.org/10.1523/JNEUROSCI.0686-09.2009; PMID: 19439587
  • Abidi SL. Chromatographic analysis of plant sterols in foods and vegetable oils. J Chromatogr A 2001; 935:173 - 201; http://dx.doi.org/10.1016/S0021-9673(01)00946-3; PMID: 11762774
  • Roberts RC. The Charcot-Marie-Tooth diseases: how can we identify and develop novel therapeutic targets?. Brain 2012; 135:3527 - 8; http://dx.doi.org/10.1093/brain/aws311; PMID: 23250878